Merck has reported results for the first quarter ended March 31, 2013.
The company has reported rise of 12.83% in its net profit at Rs 13.98 crore for the quarter ended March 31, 2013 as compared to Rs 12.39 crore for the same quarter in the previous year. Total income from operation of the company has increased by 24.37% at Rs 182.04 crore for quarter under review as compared to Rs 146.37 crore for the quarter ended March 31, 2012.
Merck is a global pharmaceutical and chemical enterprise. In the pharmaceutical segment major products include vitamins, nutritional supplement, cardio vascular, respiratory, hematinics, cough and cold, non-steroidal anti-inflammatory (NSAID), antibiotics, oral rehydration salts and encephalotropics.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: